drugset / Trial / NCT01155934

Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

NCT01155934

Phase 1 Completed 36 enrolled Dr. Reddy's Laboratories Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study was to assess the single-dose relative bioavailability study of 1 mg risperidone orally disintegrating tablets and (Risperdal M-TAB) under fed conditions.

Timeline

Start
2004-08
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 1 mg Oral

Indications

No indication recorded.